In the report, we basically saw that we could have overall savings of $4.2 billion, but again, this whole estimation was based on a very specific formulary provided to us by the House of Commons Standing Committee on Health, and that was only looking at the drugs on Quebec's public formulary. You can imagine that even if we're using a different set of drugs, the costs or the savings that we could find would change. It also excludes any drugs that were administered in hospitals.
Also, of course, it does assume that by having a single payer for these drugs in Canada we would be able to achieve a lower price from drug manufacturers. Because the request from the standing committee was part of their study, they did provide to us a very specific scenario. It is not yet a policy, so we didn't really include that in our outlook here.